THANK YOU TO OUR EXHIBITORS AND SUPPORTERS!
Please visit the following organizations virtual exhibit booths by clicking the buttons below.
Exhibitors |
AbbVie, a global, researched-based biopharmaceutical company, is committed to educating patients and caregivers about Parkinson’s disease to raise awareness about the condition, and further research to improve the lives of those living with and impacted by this disease. AbbVie is a proud sponsor of the Wisconsin Neurological Society. |
Alexion is a global biopharmaceutical company with the mission of transforming the lives of people affected by rare diseases by continuously innovating and creating meaningful value in all that we do. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. |
Allergan, a company of AbbVie, is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. |
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), MuSK antibody positive myasthenia gravis, and spinal muscular atrophy (SMA) type 3. Catalyst has launched the only evidence-based, FDA-approved treatment for adult patients with Lambert-Eaton Myasthenic Syndrome (LEMS), it's the first product approved by the FDA for LEMS in more than 35 years Coral Gables, FL | http://www.catalystpharma.com |
Neurelis, Inc. is an innovation-driven neuroscience company providing a highly differentiated approach to target unmet medical needs. Neurelis is focused on the development and commercialization of product candidates for epilepsy and the broader central nervous system (CNS) market. We are built on a foundation of people with a passion for progress in serving the needs of people with epilepsy and those who care for them. Neurelis has reached a milestone in patient care with its first FDA-approved treatment. For further information, please visit our Product Page. For more information about Neurelis, please visit http://www.neurelis.com. |
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and commercializing life-changing treatments for people with serious, challenging and under-addressed disorders. The company's diverse portfolio includes four FDA-approved treatments as well as clinical programs in multiple therapeutic areas. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms. For more information, visit neurocrine.com, and follow the company on LinkedIn. |
Sanofi Genzyme is the specialty care global business unit of Sanofi. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofigenzyme.com. MAT-US-2019647-v1.0-09/2020 |